Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

Epidermal growth factor receptor gene amplification and protein overexpression in basal-like carcinoma of the breast.

Shao MM, Zhang F, Meng G, Wang XX, Xu H, Yu XW, Chen LY, Tse GM.

Histopathology. 2011 Aug;59(2):264-73. doi: 10.1111/j.1365-2559.2011.03921.x.

PMID:
21884205
3.

EGFR expression and gene copy number in triple-negative breast carcinoma.

Gumuskaya B, Alper M, Hucumenoglu S, Altundag K, Uner A, Guler G.

Cancer Genet Cytogenet. 2010 Dec;203(2):222-9. doi: 10.1016/j.cancergencyto.2010.07.118.

PMID:
21156237
4.

Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.

Pintens S, Neven P, Drijkoningen M, Van Belle V, Moerman P, Christiaens MR, Smeets A, Wildiers H, Vanden Bempt I.

J Clin Pathol. 2009 Jul;62(7):624-8. doi: 10.1136/jcp.2008.061358.

PMID:
19561231
6.

HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.

Press MF, Finn RS, Cameron D, Di Leo A, Geyer CE, Villalobos IE, Santiago A, Guzman R, Gasparyan A, Ma Y, Danenberg K, Martin AM, Williams L, Oliva C, Stein S, Gagnon R, Arbushites M, Koehler MT.

Clin Cancer Res. 2008 Dec 1;14(23):7861-70. doi: 10.1158/1078-0432.CCR-08-1056.

7.

Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.

Kuo SJ, Wang BB, Chang CS, Chen TH, Yeh KT, Lee DJ, Yin PL, Chen M.

Taiwan J Obstet Gynecol. 2007 Jun;46(2):146-51.

8.
9.

EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast.

Vranic S, Tawfik O, Palazzo J, Bilalovic N, Eyzaguirre E, Lee LM, Adegboyega P, Hagenkord J, Gatalica Z.

Mod Pathol. 2010 May;23(5):644-53. doi: 10.1038/modpathol.2010.50. Epub 2010 Mar 5.

11.

Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study.

Rodríguez-Pinilla SM, Rodríguez-Gil Y, Moreno-Bueno G, Sarrió D, Martín-Guijarro Mdel C, Hernandez L, Palacios J.

Am J Surg Pathol. 2007 Apr;31(4):501-8.

PMID:
17414096
12.

Frequent overexpression of epidermal growth factor receptor (EGFR) in mammary high grade ductal carcinomas with myoepithelial differentiation.

Shien T, Tashiro T, Omatsu M, Masuda T, Furuta K, Sato N, Akashi-Tanaka S, Uehara M, Iwamoto E, Kinoshita T, Fukutomi T, Tsuda H, Hasegawa T.

J Clin Pathol. 2005 Dec;58(12):1299-304.

13.
14.

Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.

Shah SS, Ketterling RP, Goetz MP, Ingle JN, Reynolds CA, Perez EA, Chen B.

Hum Pathol. 2010 Jan;41(1):103-6. doi: 10.1016/j.humpath.2009.07.001. Epub 2009 Sep 16.

PMID:
19762065
15.

Adenoid cystic carcinomas of the breast have low Topo IIα expression but frequently overexpress EGFR protein without EGFR gene amplification.

Vranic S, Frkovic-Grazio S, Lamovec J, Serdarevic F, Gurjeva O, Palazzo J, Bilalovic N, Lee LM, Gatalica Z.

Hum Pathol. 2010 Nov;41(11):1617-23. doi: 10.1016/j.humpath.2010.04.013. Epub 2010 Aug 4.

PMID:
20688355
16.

Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma.

Kersting C, Tidow N, Schmidt H, Liedtke C, Neumann J, Boecker W, van Diest PJ, Brandt B, Buerger H.

Lab Invest. 2004 May;84(5):582-7.

17.

HER2 status in breast cancer determined by IHC and FISH: comparison of the results.

Mrozkowiak A, Olszewski WP, Piaścik A, Olszewski WT.

Pol J Pathol. 2004;55(4):165-71.

PMID:
15757204
18.

Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.

Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P.

Breast J. 2005 Jul-Aug;11(4):278-80.

PMID:
15982396
19.

Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression.

Tsuda H, Akiyama F, Terasaki H, Hasegawa T, Kurosumi M, Shimadzu M, Yamamori S, Sakamoto G.

Cancer. 2001 Dec 15;92(12):2965-74.

PMID:
11753973
20.

Epidermal growth factor receptor gene status by fluorescence in situ hybridization in malignant, atypical, and benign hidradenomas.

Piris A, Scopsi L, Clemente C, Cetti Serbelloni F, Mihm MC Jr, Hoang MP.

Am J Dermatopathol. 2010 Aug;32(6):586-92. doi: 10.1097/DAD.0b013e3181cd64f2.

PMID:
20534988

Supplemental Content

Support Center